Literature DB >> 34199886

Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma.

Yuto Hozaka1, Naohiko Seki2, Takako Tanaka1, Shunichi Asai2, Shogo Moriya3, Tetsuya Idichi1, Masumi Wada1, Kiyonori Tanoue1, Yota Kawasaki1, Yuko Mataki1, Hiroshi Kurahara1, Takao Ohtsuka1.   

Abstract

The aggressive nature of intrahepatic cholangiocarcinoma (ICC) renders it a particularly lethal solid tumor. Searching for therapeutic targets for ICC is an essential challenge in the development of an effective treatment strategy. Our previous studies showed that the miR-29-3p-family members (miR-29a-3p, miR-29b-3p and miR-29c-3p) are key tumor-suppressive microRNAs that control many oncogenic genes/pathways in several cancers. In this study, we searched for therapeutic targets for ICC using the miR-29-3p-family as a starting point. Our functional studies of cell proliferation, migration and invasion confirmed that the miR-29-3p-family act as tumor-suppressors in ICC cells. Moreover, in silico analysis revealed that "focal adhesion", "ECM-receptor", "endocytosis", "PI3K-Akt signaling" and "Hippo signaling" were involved in oncogenic pathways in ICC cells. Our analysis focused on the genes for integrin-α6 (ITGA6) and integrin-β1 (ITGB1), which are involved in multiple pathways. Overexpression of ITGA6 and ITGB1 enhanced malignant transformation of ICC cells. Both ITGA6 and ITGB1 were directly regulated by the miR-29-3p-family in ICC cells. Interestingly, expression of ITGA6/ITGB1 was positively controlled by the transcription factor SP1, and SP1 was negatively controlled by the miR-29-3p-family. Downregulation of the miR-29-3p-family enhanced SP1-mediated ITGA6/ITGB1 expression in ICC cells. MicroRNA-based exploration is an attractive strategy for identifying therapeutic targets for ICC.

Entities:  

Keywords:  ITGA6; ITGB1; SP1; intrahepatic cholangiocarcinoma; miR-29a-3p; miR-29b-3p; miR-29c-3p; tumor-suppressor

Year:  2021        PMID: 34199886     DOI: 10.3390/cancers13112804

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.

Authors:  Congjun Wang; Ye Wang; Zhao Fu; Weijia Huang; Zhu Yu; Jiancheng Wang; Kaitian Zheng; Siwen Zhang; Shen Li; Junqiang Chen
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

2.  Negatively Regulated by miR-29c-3p, MTFR1 Promotes the Progression and Glycolysis in Lung Adenocarcinoma via the AMPK/mTOR Signalling Pathway.

Authors:  Yongmeng Li; Yanfei Liu; Kai Jin; Rui Dong; Cun Gao; Libo Si; Zitong Feng; Huiying Zhang; Hui Tian
Journal:  Front Cell Dev Biol       Date:  2021-12-01

3.  Molecular Pathogenesis of the Coronin Family: CORO2A Facilitates Migration and Invasion Abilities in Oral Squamous Cell Carcinoma.

Authors:  Ikuko Kase-Kato; Shunichi Asai; Chikashi Minemura; Kenta Tsuneizumi; Sachi Oshima; Ayaka Koma; Atsushi Kasamatsu; Toyoyuki Hanazawa; Katsuhiro Uzawa; Naohiko Seki
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

Review 4.  Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway.

Authors:  Geofrey Mahiki Mranda; Zhi-Ping Xiang; Jun-Jian Liu; Tian Wei; Yinlu Ding
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

Review 5.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

6.  Impact of miR-1/miR-133 Clustered miRNAs: PFN2 Facilitates Malignant Phenotypes in Head and Neck Squamous Cell Carcinoma.

Authors:  Shunichi Asai; Ayaka Koma; Nijiro Nohata; Takashi Kinoshita; Naoko Kikkawa; Mayuko Kato; Chikashi Minemura; Katsuhiro Uzawa; Toyoyuki Hanazawa; Naohiko Seki
Journal:  Biomedicines       Date:  2022-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.